0000950170-24-079689.txt : 20240701 0000950170-24-079689.hdr.sgml : 20240701 20240701164117 ACCESSION NUMBER: 0000950170-24-079689 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240627 FILED AS OF DATE: 20240701 DATE AS OF CHANGE: 20240701 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Catinazzo Thomas CENTRAL INDEX KEY: 0001818261 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39385 FILM NUMBER: 241091268 MAIL ADDRESS: STREET 1: C/O RELAY THERAPEUTICS, INC. STREET 2: 399 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Relay Therapeutics, Inc. CENTRAL INDEX KEY: 0001812364 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 399 BINNEY STREET STREET 2: 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-370-8837 MAIL ADDRESS: STREET 1: 399 BINNEY STREET STREET 2: 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 ownership.xml 4 X0508 4 2024-06-27 0001812364 Relay Therapeutics, Inc. RLAY 0001818261 Catinazzo Thomas C/O RELAY THERAPEUTICS, INC. 399 BINNEY STREET, 2ND FLOOR CAMBRIDGE MA 02139 false true false false Chief Financial Officer true Common Stock 2024-06-27 4 S false 295 6.26 D 339508 D Common Stock 2024-06-27 4 S false 9078 6.24 D 330430 D Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of restricted stock units ("RSUs") on June 26, 2024. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. Includes 304,929 shares underlying RSUs. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 15, 2024. This transaction was executed in multiple trades at prices ranging from $6.12 to $6.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. /s/ Thomas Catinazzo 2024-07-01